ModifiedUnitedHealthcarePolicy CS004.R

Therapeutic Apheresis (including Plasma Exchange, Photopheresis, LDL Apheresis, Immunoadsorption)

Governs medical necessity and coverage criteria for therapeutic apheresis procedures, listing conditions considered proven/medically necessary and those considered unproven/not medically necessary, with coding and documentation guidance.

Policy Summary

PayerUnitedHealthcare

PolicyTherapeutic Apheresis (coverage criteria for plasma exchange, photopheresis, LDL apheresis, immunoadsorption)

Policy CodePolicy CS004.R

Change TypeRevised coverage rationale languagetemplate/state update

Effective DateDec 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization and submit supporting clinical documentation (diagnosis, prior therapies, biomarker values such as triglycerides or HLA antibody MFI, and planned number of sessions) when requesting therapeutic apheresis.

SourceLink

POLICY UPDATE CHANGES

Replaced language that previously labeled therapeutic apheresis and photopheresis as unproven and not medically necessary for treating the listed conditions/diagnoses with language specifying they are unproven and not medically necessary for treating any other conditions/diagnoses not listed in the policy as proven and medically necessary.

Removed content/language pertaining to the state of Louisiana.

~60+listed conditions

multiplereferenced CPT codes

predominantly insufficientevidence quality

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

cryoglobulinemia articles

Coverage Criteria for Therapeutic Apheresis

Medically Necessary Indications (selected)

Medically necessary indications for therapeutic apheresis (selected conditions) — therapeutic apheresis is considered proven and medically necessary for the following diagnoses when performed according to standard clinical protocols and concurrently with disease-directed therapy where applicable:

Acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome), primary treatment

Acute liver failure requiring high-volume therapeutic plasma exchange (TPE-HV)

Anti-glomerular basement membrane disease with dialysis independence or diffuse alveolar hemorrhage

Chronic acquired demyelinating polyneuropathies (including IgG/IgA/IgM-related and anti-myelin-associated glycoprotein)

Chronic inflammatory demyelinating polyneuropathy

Cryoglobulinemia, as second-line/adjuvant therapy for severe renal involvement (TA modalities such as PE, PP, and CF shown effective when combined with immunosuppression)

Dilated cardiomyopathy, idiopathic, NYHA class II-IV via immunoadsorption

Familial hypercholesterolemia (homozygous: lipoprotein apheresis; heterozygous: lipoprotein apheresis as second-line; all patients via therapeutic plasma exchange when indicated)

Focal segmental glomerulosclerosis, recurrent in transplanted kidney, second-line therapy

Graft-versus-host disease (acute; chronic as second-line)

Hereditary hemochromatosis (when apheresis modality indicated)

Hypertriglyceridemic pancreatitis, severe (plasmapheresis to rapidly reduce triglycerides)

Hyperviscosity syndromes associated with hypergammaglobulinemia

Inflammatory bowel disease (ulcerative colitis, Crohn’s disease) via adsorptive cytapheresis (GMA/L-GCAP) as adjunctive therapy in selected refractory cases

Lipoprotein(a) hyperlipoproteinemia (lipoprotein apheresis)

Multiple sclerosis, acute attack or relapse, second-line therapy

Myasthenia gravis, acute

Myeloma cast nephropathy (light chain cast nephropathy), second-line/adjuvant to chemotherapy

Neuromyelitis optica spectrum disorders (NMOSD), acute or relapse, as second-line/adjuvant therapy including plasma exchange for acute optic neuritis (see evidence summary)

N-methyl D-aspartate receptor antibody encephalitis

Pediatric autoimmune neuropsychiatric disorders (PANDAS/PANS) exacerbation (selected refractory cases)

Peripheral vascular diseases when apheresis indicated

Progressive multifocal leukoencephalopathy associated with natalizumab (as indicated)

Pruritus due to hepatobiliary disease, treatment resistant

Rheumatoid arthritis, refractory, second-line therapy (leukocytapheresis/Prosorba PCT)

Sickle cell disease: acute stroke or multiorgan failure; acute chest syndrome severe (second-line exchange transfusion); stroke prophylaxis and individuals requiring chronic transfusion programs

Thrombotic thrombocytopenic purpura (TTP)

Transplantation indications (heart, kidney, liver, lung, hematopoietic stem cell) including desensitization, antibody-mediated rejection management, cellular rejection, and ABO-incompatible procedures in selected pediatric patients

Transplant and Lipoprotein Indications — additional medically necessary conditions (selected)

Transplantation and lipoprotein-specific indications — additional clinically accepted uses:

Heart transplantation: apheresis (including extracorporeal photopheresis) for rejection prophylaxis and treatment, and desensitization as second-line adjunct

Kidney transplantation: antibody-mediated rejection treatment; peri-transplant desensitization/prophylaxis for living donors; ABO-incompatible kidney transplant desensitization (second-line)

Liver transplantation: desensitization for ABO-incompatible living donors via therapeutic plasma exchange

Lung transplantation: bronchiolitis obliterans syndrome and chronic lung allograft dysfunction management with apheresis modalities

Hematopoietic stem cell transplantation (HSCT): management of ABO incompatibility (HPC(A), HPC(M)) and related indications

NMOSD: PLEX for Acute Optic Neuritis (Adjunctive/Second-Line)

Neuromyelitis Optica Spectrum Disorder (NMOSD) — clinical evidence and coverage stance for plasma exchange (PLEX) in acute optic neuritis:

PLEX may be considered as second-line or adjunctive therapy for acute optic neuritis in NMO/NMOSD when first-line high-dose corticosteroids are ineffective or contraindicated.

Evidence summary: A systematic review and meta-analysis identified mostly observational studies (no high-quality RCT evidence). In pooled observational data (n=32 with pre- and post-treatment visual acuity), improvements in visual acuity after PLEX were inconsistent and statistically non-significant at multiple post-treatment time points. Heterogeneity, small sample sizes, and retrospective study designs limit certainty.

Clinical recommendation: PLEX is medically reasonable as a second-line/adjuvant intervention for severe acute ON in NMOSD when used in conjunction with disease-directed therapy and when treating clinicians document failure or intolerance of first-line therapy. Prior authorization documentation should include severity, prior treatments tried, and planned concurrent disease-directed therapy.

Pediatric ABO-Incompatible Heart Transplantation — plasma exchange or immunoadsorption

Pediatric ABO-Incompatible Heart Transplantation — plasma exchange or immunoadsorption considerations:

Indications: Perioperative plasma exchange (ABO-PE) or intraoperative anti-A/B immunoadsorption (ABO-IA) may be used to reduce isohemagglutinin titers to enable ABO-incompatible heart transplantation in pediatric patients.

Evidence summary: Retrospective series demonstrate comparable early survival and rejection rates between ABO-IA, ABO-PE, and ABO-compatible transplants. ABO-IA was associated with significantly lower blood product transfusion volumes and permitted transplantation in older pediatric recipients in some series. Data are from nonrandomized observational cohorts with limited sample sizes.

Clinical recommendation: ABO-PE or ABO-IA for pediatric ABO-incompatible heart transplantation is an accepted clinically necessary practice in appropriately selected pediatric recipients when performed according to institutional transplant protocols. Documentation should include pre- and post-procedure isohemagglutinin titers, patient age/weight, and institutional transplant desensitization protocol.

Kawasaki Disease — PE as Prophylaxis After IVIG Failure

Kawasaki Disease — plasma exchange (PE) as prophylaxis after IVIG failure:

Indication: In children with Kawasaki disease who remain IVIG-refractory and who are assessed to be at high risk for coronary artery lesions (based on rising inflammatory markers or clinical risk features), therapeutic plasma exchange may be considered as a prophylactic intervention to reduce the risk of coronary artery complications.

Evidence summary: A retrospective study reported lower rates of coronary artery lesions among IVIG-refractory children treated with PE versus additional IVIG, with no PE-related complications reported in that series. Evidence is limited to observational studies and cannot establish definitive efficacy.

Clinical recommendation: PE may be considered in IVIG-refractory, high-risk Kawasaki disease as an adjunct to escalate therapy when standard treatments fail. Prior authorization should document IVIG treatment history, markers indicating high risk for coronary artery lesions, and planned timing of PE relative to IVIG courses.

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization and Documentation

Prior authorization may be required for therapeutic apheresis procedures. Verify member-specific federal, state, and contractual benefit plan requirements prior to scheduling. Medical records documentation may be required to assess whether the member meets clinical criteria for coverage; lack of adequate documentation may result in denial.

Confirm PA requirements against the member's benefit plan and applicable laws prior to service.
Medical records to support review may include history, physical exam, lab values, prior treatments, and specialist notes.

Documentation Required

HTG-AP: Include Triglyceride and Severity Markers

For hypertriglyceridemic acute pancreatitis (HTG-AP) requests, include current triglyceride (TG) level and objective markers of disease severity (for example BISAP score, organ failure, lactate, vasopressor use). These data assist in determining urgency and appropriateness of apheresis.

Coding and Procedure Codes

Referenced CPT CodeCPT

0342T

Therapeutic apheresis with selective HDL delipidation and plasma reinfusion

Additional CPT Codes in DescriptionsCPT

36511	Therapeutic apheresis; for white blood cells.
36512	Therapeutic apheresis; for red blood cells.
36513	Therapeutic apheresis; for platelets.
36514	Therapeutic apheresis; for plasma pheresis.
36516	Therapeutic apheresis; with extracorporeal immunoadsorption, selective adsorption or selective filtration and plasma reinfusion.
36522	Photopheresis, extracorporeal.

Referenced HCPCS/S-codeHCPCS

S2120

Low density lipoprotein (LDL) apheresis using heparin-induced extracorporeal LDL precipitation

HLA antibody MFI — thresholds and desensitization context

Reported MFI examplesStudies report pre-treatment HLA antibody MFI values >2,000 as detectable and describe 'strongly positive' values >10,000.

Typical reduction with PA-IAAfter 10 PA-IA sessions mean MFI reductions reported: class I ~66.8% and class II ~71.1%.

Differential clearance by class and baseline MFIStrongly positive (MFI >10,000) class II antibodies showed greater proportional reduction than strongly positive class I in reported series.

Triglyceride level and study thresholds for HTG‑AP / apheresis consideration

24-hour TG reductionPlasmapheresis reduced triglycerides more rapidly within 24 hours versus medical therapy (example: 70.4% vs 59.7% TG reduction at 24 h in Sahin et al.).

Definitions and Procedures

Plasma exchange (plasmapheresis) — definition

DefinitionPlasma exchange (plasmapheresis) is a machine-assisted procedure that separates and removes plasma from blood cells and replaces the plasma with a solution prior to reinfusion.

Typical settingUsually performed in an outpatient facility and can take several hours; in some situations plasma exchange may be performed daily for at least 1 week.

PurposeUsed to remove pathogenic plasma constituents (e.g., autoantibodies, immune complexes, free light chains) with replacement fluid to restore homeostasis.

Extracorporeal photopheresis (ECP) / Photopheresis — definition

DefinitionExtracorporeal photopheresis (ECP) is a procedure in which a patient's buffy coat is separated, treated extracorporeally with a photoactive compound (e.g., psoralens / UVADEX) and exposed to ultraviolet A light, then reinfused during the same procedure.

Line of Therapy and Treatment Intent

second-line

Indications generally considered second-line (adjunctive or reserved after standard therapies):

Second-line indications: Examples include cryoglobulinemia, recurrent FSGS in transplanted kidney, graft-versus-host disease (chronic), multiple sclerosis acute relapse, myeloma cast nephropathy (adjunct to chemotherapy), neuromyelitis optica acute ON, and other conditions identified in the policy as second-line.

Document prior/concurrent disease-directed therapies and multidisciplinary rationale.

second-line

Additional second-line designation examples:

Second-line/adjunctive contexts: Plasmapheresis/TPE used as adjunct to chemotherapy in MM with AKI/cast nephropathy and immunoadsorption in selected cardiomyopathy or transplant desensitization contexts; use is contingent on concurrent appropriate therapies.

Evidence supports adjunctive rather than standalone use in several indications.

Biomarker and Laboratory Requirements

Serum free light chains (sFLC) — biomarker requirement for MM cast nephropathy

Biomarker requirementSerum free light chains (sFLC) measurement is required as part of evaluation when considering plasmapheresis adjunct in multiple myeloma with suspected cast nephropathy/AKI.

Clinical contextsFLCs are used to document the burden of pathogenic light chains and to monitor response to plasmapheresis combined with chemotherapy.

Documentation noteAuthorization requests should include baseline sFLC levels and dialysis status to support adjunctive plasmapheresis decisions per policy evidence summaries.

Serum free light chains (sFLC) — elevated levels and dialysis‑dependence in study populations

Threshold/context from studiesStudies suggest significant elevation of sFLC and dialysis‑dependence or severe AKI were features of populations most likely to benefit from adjunct plasmapheresis; greater benefit observed with >3 sessions in some analyses.

Background on Therapeutic Apheresis

Therapeutic apheresis encompasses extracorporeal procedures that selectively remove or exchange blood components, including plasma exchange (plasmapheresis), immunoadsorption, high-volume plasma exchange, extracorporeal photopheresis, lipoprotein apheresis, and red blood cell exchange. These procedures remove targeted plasma constituents (for example, autoantibodies, free light chains, lipoproteins, or cellular elements) and may include replacement with colloid/crystalloid solutions or reinfusion of treated cellular components. Typical settings range from outpatient to intensive inpatient care, and treatment courses can require single-session urgent interventions or multiple daily/serial sessions over several days depending on the clinical indication.

Policy Revision History and Changes

2026-04-01template_update

Removed content/language pertaining to the state of Louisiana; updated supporting information (Clinical Evidence, FDA, and References) and archived prior version CS004.Q.

2025-12-01coverage_rationale_revisionLatest

Revised coverage rationale wording to narrow prior phrasing by specifying that therapeutic apheresis (including plasmapheresis and photopheresis) is unproven and not medically necessary for any other conditions/diagnoses not listed as proven and medically necessary (policy CS004.R effective 2025-12-01).

Policy Summary

PayerUnitedHealthcare

PolicyTherapeutic Apheresis (coverage criteria for plasma exchange, photopheresis, LDL apheresis, immunoadsorption)

Policy CodePolicy CS004.R

Change TypeRevised coverage rationale languagetemplate/state update

Effective DateDec 1, 2025

Next Review DateN/A

SourceLink

On This Page

Lipoprotein apheresis (LA): indicated for homozygous familial hypercholesterolemia and for selected patients with elevated lipoprotein(a) where medical therapy is insufficient

Document pre-treatment TG and timing relative to symptom onset/admission.

Provide severity markers (BISAP, organ dysfunction, ICU admission) when requesting urgent TPE for HTG-AP.

Prior Authorization

Prior Authorization for Chronic/Transfusion Programs

Prior authorization is recommended for chronic transfusion and chronic red cell exchange (RCE) programs and for RBC-primed pediatric procedures to ensure appropriate patient selection, scheduling, and resource planning.

For chronic transfusion/RCE include indication, transfusion frequency (e.g., receiving transfusions once every 5 weeks or more frequently), prior AE history, and monitoring plan.
For RBC-primed pediatric procedures include patient weight, prior tolerance, and program enrollment documentation.

Prior Authorization

Prior Authorization Recommended for Sepsis with MOD and AAV

Adjunctive apheresis for sepsis with multiorgan dysfunction (MOD) or ANCA-associated vasculitis (AAV) may be considered but evidence is variable; prior authorization is recommended so that benefit/risk and contemporaneous evidence can be reviewed.

For sepsis/MOD include organ dysfunction details, timing of TPE relative to sepsis onset, and concurrent therapies.
For AAV include ANCA status, renal involvement, dialysis need, and prior immunosuppressive treatments.

Prior Authorization

Prior Authorization for Leukapheresis/Plasmapheresis in Hematologic Indications

Prior authorization is recommended for leukapheresis and plasmapheresis when used for specific hematologic indications (for example leukostasis in life‑threatening acute promyelocytic leukemia or hyperviscosity in multiple myeloma). Requests should document urgency and failure or unsuitability of alternative measures.

For leukapheresis in APL/leukostasis, document WBC count, clinical evidence of leukostasis, and attempts at cytoreduction.
For plasmapheresis in hyperviscosity, document serum viscosity or clinical hyperviscosity signs and hematologic diagnosis.

Documentation Required

Durability and Timing of Desensitization

Desensitization protocols reduce HLA antibody levels but are not durable unless transplantation occurs soon after treatment. Document antibody measurements pre- and post-procedure and the planned timing of transplant relative to last apheresis session.

Provide MFI values (or PRA) before treatment and after each session where available, and the number of planned and completed sessions.
State expected transplant timing; benefits of desensitization are limited if transplant will be delayed.

Denial Risk

Evidence Gaps and Denial Risk

Requests for indications with limited or insufficient evidence (for example Alzheimer’s disease, Sydenham's chorea, TEN, Kawasaki disease, steroid‑resistant native FSGS) should include supportive rationale; absence of convincing evidence may trigger denial.

Alzheimer's disease (mild/moderate): insufficient high‑quality evidence — potential denial risk without strong trial support.
FSGS (steroid‑resistant native kidney): insufficient evidence for benefit — potential denial risk for TPE or LDL apheresis.
Unlisted or low‑evidence indications: coverage determinations will follow policy rationale; requests may be denied.

Documentation Required

Required Supporting Clinical Documentation

Provide required supporting clinical documentation for pediatric ABO‑incompatible transplants, PANDAS/PANS, and other high‑risk or limited‑evidence indications to allow thorough review. Missing documentation may lead to denial.

Include indication, detailed prior therapies and responses, and relevant laboratory and imaging data.
For pediatric ABO‑incompatible transplants include isohemagglutinin titers, transfusion history, and transplant timing.

Documentation Required

Supporting Documentation for High‑Risk / Limited‑Evidence Indications

For high‑risk or limited‑evidence indications (including second‑line therapy uses), document diagnosis, prior guideline‑recommended therapies and failures, refractory or life‑threatening status, and rationale for apheresis as next step.

Second‑line therapy examples: cryoglobulinemia, recurrent FSGS in transplant, graft‑versus‑host disease — document prior first‑line treatments and reasons for failure.
IBD requests (ulcerative colitis/CAP/GMA): document prior biologics, immunomodulators, thiopurine or steroid failures and timing of those therapies.

Note

Multidisciplinary Consultation Recommended

A multidisciplinary consultation and specialty review (for example pediatric neurologist, rheumatologist, hematologist, transplant team) is recommended for complex immunomodulatory apheresis decisions such as PANS/PANDAS, desensitization, refractory autoimmune disease, or pediatric chronic transfusion programs.

Document specialty consultation notes and consensus plan when available.
AAP guidance for PANS recommends multidisciplinary team evaluation before immunomodulatory therapies.

Step Therapy

Step Therapy and Prior Treatment Exhaustion

Step‑therapy expectations: exhaust standard, guideline‑recommended therapies before apheresis for conditions where evidence is low or apheresis is designated second‑line. Document prior use and failure of standard therapies.

Examples: GMA for IBD — document failure or intolerance to thiopurines, immunomodulators, and biologics per the indication.
For conditions labeled second‑line by ASFA or other guidelines, include timeline and objective measures showing failure of first‑line treatments.

Study-level TG cutoffsStudies used varying elevated TG levels; no single uniform triglyceride cutoff was established across analyses.

LA RCT threshold for lipoprotein(a)A small RCT of lipoprotein apheresis used lipoprotein(a) >500 mg/L as an inclusion threshold in a refractory angina study (Khan).

Billing Rule

Procedure codes referenced for authorization (duplicate emphasis)

Prior authorization may apply to the same procedure codes highlighted elsewhere in the policy; include CPT 0342T and CPT codes 36511–36516, 36522, and HCPCS S2120 when submitting authorization requests for therapeutic apheresis.

Repeat reference codes for authorization: 0342T; 36511–36516; 36522; S2120.

The Therakos/ UVAR systems and the photoactive agent UVADEX are FDA‑regulated; UVADEX has received orphan drug designations for several indications.

Typical useECP is used for selected immune-mediated and dermatologic conditions (e.g., CTCL) as a palliative or immunomodulatory therapy under device/agent approvals or guideline recommendations.

High‑volume plasma exchange (HVP/HVPE) — definition and volumes

Definition and volumeHigh‑volume plasma exchange (HVP/HVPE) is defined as exchange of ~15% of ideal body weight, representing approximately 8–12 liters of plasma removed.

Exchange rateReported plasma removal rates are approximately 1–2 L per hour with replacement by plasma in equivalent volume.

Indications/contextUsed in select critical indications where larger plasma clearance is desired (e.g., acute liver failure trials); modality requires intensive monitoring.

Immunoadsorption (IA) — selective immunoadsorption

DefinitionImmunoadsorption (IA) is a procedure in which separated plasma is passed through a device that specifically binds and removes immunoglobulins (e.g., via protein A or other ligands).

SelectivityIA selectively targets immunoglobulins and can be used to reduce pathogenic antibodies while returning treated plasma components to the patient.

Clinical useApplied for desensitization (e.g., pre‑transplant) and autoimmune conditions where targeted antibody removal is desired.

Plasma exchange / plasmapheresis — role in cryoglobulinemia and other uses

Role in cryoglobulinemiaPlasma exchange/plasmapheresis is used as adjunctive therapy with immunosuppression for severe cryoglobulinemic vasculitis with renal involvement; pooled TA response rates reported ~78%.

Other clinical usesPLEX is also used to remove pathogenic plasma constituents in transplant desensitization, hypertriglyceridemic pancreatitis, myasthenia gravis, and other immune‑mediated diseases.

Modality equivalenceIn cryoglobulinemia systematic reviews PE, PP, and cryofiltration had comparable renal outcome rates, with PE most commonly deployed.

Protein A immunoadsorption (PA‑IA) — selective technique to reduce HLA antibody MFI

TechniqueProtein A immunoadsorption (PA‑IA) is a selective immunoadsorption method that binds immunoglobulins (including HLA antibodies) to lower antibody levels.

Effect on HLA MFIPA‑IA has been shown to substantially reduce HLA antibody MFI with documented mean reductions after multiple sessions (see reported class I/II reductions after 10 sessions).

Clinical applicationUsed in peri‑transplant desensitization protocols to reduce antibody burden prior to transplantation; often combined with immunosuppressive drugs (e.g., rituximab).

Lipoprotein apheresis (LA) — definition and clinical use

DefinitionLipoprotein apheresis (LA) is an extracorporeal procedure to selectively reduce LDL cholesterol and lipoprotein(a) levels and return remaining blood components to the patient.

Clinical useIndicated in refractory familial hypercholesterolemia (including homozygous FH) and for select patients with elevated lipoprotein(a) and refractory angina in evidence‑limited settings.

Frequency effectMore frequent treatments (weekly or twice weekly) produce greater LDL‑C lowering; in registry data some pediatric patients achieved LDL‑C <3.5 mmol/L with weekly or twice‑weekly therapy.

Plasmapheresis / plasma exchange (PLEX) — definition and adjunctive role

DefinitionPlasmapheresis / plasma exchange (PLEX) is the extracorporeal removal of plasma components (e.g., free light chains, antibodies) combined with replacement fluid and is frequently used as an adjunct to disease‑directed therapies.

Adjunctive rolePLEX is commonly used adjunctively (e.g., myeloma cast nephropathy combined with chemotherapy) rather than as standalone definitive therapy in many indications.

Procedure logisticsProcedures are typically performed in outpatient settings but may be daily for critical indications; number of sessions varies by indication and response.

Red cell exchange (RCE) / automated RBC exchange — definition and use in SCD

DefinitionRed cell exchange (RCE) or automated RBC exchange is a procedure exchanging a patient’s red blood cells for donor RBCs to reduce sickle hemoglobin fraction.

Use in SCDUsed to treat or prevent complications of sickle cell disease (e.g., acute chest syndrome, stroke prophylaxis) and can be automated or RBC‑primed for small children.

Safety observationsProspective and retrospective series report low incidence of severe complications with appropriate monitoring; pediatric RBC‑primed techniques have been shown safe in small series.

PLEX / Plasma exchange (PE) — definition and evaluation in AAV and immune disorders

DefinitionPLEX/Plasma exchange (PE) is the extracorporeal removal and replacement of plasma evaluated as adjunctive therapy in ANCA‑associated vasculitis (AAV) and other immune‑mediated diseases.

Evidence summary in AAVMeta‑analyses and RCTs show no consistent reduction in overall mortality or relapse with PLEX, though some analyses indicate reduced short‑term ESRD incidence in early treatment phases.

Coverage implicationUse in AAV should be individualized and may require prior authorization and supporting documentation for high‑risk renal failure cases.

TPE (therapeutic plasma exchange) — adjunctive removal in critically ill patients

DefinitionTherapeutic plasma exchange (TPE) refers to adjunctive removal of plasma components in critically ill patients, including trials of adjunct TPE in sepsis with multiorgan dysfunction.

Evidence in sepsis/MODSA meta‑analysis of small trials suggested adjunct TPE using donor plasma may reduce short‑term mortality (RR 0.59, 95% CI 0.47–0.74), but evidence is limited by trial sizes and heterogeneity.

Clinical use noteConsidered on a case‑by‑case basis in critically ill patients with documentation and prior authorization given limited and variable evidence.

Therapeutic apheresis — overall definition and device/setting context

DefinitionTherapeutic apheresis encompasses procedures that remove or exchange blood components (plasma, leukocytes, RBCs, platelets) using FDA‑regulated devices to treat or palliate disease states.

Settings/devicesProcedures are performed using centrifugation or filtration devices; filtration‑based separators are Class III devices and device/agent approvals (e.g., ECP systems) exist.

Procedural contextMay be performed outpatient or inpatient depending on indication; frequency and number of sessions are indication‑dependent and documented in policy evidence summaries.

UVADEX photopheresis agent — agent name and orphan designations

Agent nameUVADEX (8‑methoxypsoralen) — photoactive agent used with extracorporeal photopheresis systems.

Regulatory/orphan designationsUVADEX has FDA Orphan Drug designations for diffuse systemic sclerosis, graft‑versus‑host disease (GVHD), and prevention of acute rejection of cardiac allografts.

Use pairingUVADEX is used in conjunction with ECP systems (e.g., UVAR XTS or Therakos CELLEX) for approved and some off‑label immunomodulatory indications.

salvage

Salvage therapy contexts where apheresis may be considered only in life-threatening, unresponsive situations:

Salvage use (example): Leukapheresis for life-threatening leukostasis in acute promyelocytic leukemia unresponsive to other modalities is considered salvage and used with caution; similarly, other apheresis modalities may be considered as salvage in exceptional cases per specialty guidance.

Follow NCCN and institutional guidance for salvage indications; prior authorization encouraged.

Session effectObservational reports note mean number of TPE sessions around 3–4, with larger FLC reductions and improved renal outcomes associated with >3 sessions in some cohorts.

Adjunctive requirementPlasmapheresis benefit in MM cast nephropathy is reported when combined with effective chemotherapy (e.g., bortezomib‑containing regimens) rather than as monotherapy.

Regimen / Setting	Details
Plasmapheresis performed over multiple sessions (mean 3–4 sessions)	Evidence indicates greater benefit with more sessions (>3); plasmapheresis reduces serum free light chains (sFLC) when combined with concurrent chemotherapy (e.g., bortezomib-containing regimens). Studies report significant FLC reductions and lower dialysis‑dependence rates when plasmapheresis is added to chemotherapy compared with chemotherapy alone.